20091005
 Health & Wellness: Cancer Drug Backed By FDA Expert Panel   By Jennifer Corbett Dooren, The Wall Street Journal,  Oct 6, 2009  The panel of outside medical experts voted six to four in favor of a question that asked if there was a favorable risk-benefit assessment for Pegintron for the treatment of patients with Stage III melanoma, or cancer that has spread to lymph nodes.   
